Abbisko Cayman Limited
HHKEX:22566.92
HKD
-0.12
(-1.71%)
Abbisko Cayman Limited
HKEX:2256
(Hong Kong Exchange)
Recent
price
6.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Abbisko Cayman Limited (2256.HK) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies targeting unmet medical needs in oncology and other therapeutic areas. The company offers a pipeline of small molecule and antibody-drug conjugate (ADC) candidates, including core products such as ABSK011, a selective FGFR3 inhibitor for cholangiocarcinoma and other FGFR3-driven tumors; ABSK012, a next-generation TROP2-targeted ADC for solid tumors; ABSK014, a CDK7 inhibitor for oncology indications; and earlier-stage assets like ABSK003 (SHP2 inhibitor) and ABSK007 (SOS1 inhibitor), all advancing through preclinical and clinical trials. Operations span research and development primarily in China, with headquarters in Cayman Islands and key facilities in Shanghai, China, where the company was founded in 2018. In recent developments, Abbisko has expanded its pipeline through strategic licensing agreements, including partnerships for ADC technologies, and reported positive interim data from Phase I/II trials of ABSK011 in 2024, alongside preparations for multiple Phase II/III initiations; the company also completed a Hong Kong IPO in November 2023 raising approximately HK$1.2 billion to fund late-stage clinical programs and manufacturing scale-up. Abbisko targets global markets with a focus on Asia-Pacific oncology patients, operating through its Shanghai-based subsidiary Abbisko Therapeutics Co., Ltd. and collaborations with international CROs for clinical execution.